With the financing, Avrobio plans to push its pipeline through the clinic "as aggressively as possible."

Warp Drive has been working to live up to its name, speeding through development and deals.

Corbus will enroll 415 patients in a phase 2b trial using pulmonary exacerbations as its primary endpoint.

XtalPi combines AI, quantum physics and cloud computing to predict drugs’ crystal structures more quickly and accurately.

The startup draws on the same striking mix of investors that have powered natural killer cell player Dragonfly Therapeutics to a deal with Celgene.

Disarm has poached Big Pharma executive Thomas Engber, Ph.D., as its new SVP and head of neuropharmacology and translational sciences.

Tmunity will develop its T-cell therapies first using UPenn's facilities and eventually expanding to its own sites.

Eureka Therapeutics will advance its T-cell treatment for relapsed and refractory CD19+ non-Hodgkin lymphoma into the clinic.

In response to declining venture investment in some disease areas, BIO is releasing reports to identify barriers to innovation.